

Contributors

- A. C. Altamura, *Associate Professor of Psychiatry, Università degli Studi di Milano, Cattedra di Clinica Psichiatrica, Ospedale Maggiore, Via F. Sforza 35, Milan, Italy*
- J. N. Beuzen, *Lilly France, 92213, Saint-Cloud, France*
- R. F. Bergstrom, *Lilly Laboratory for Clinical Research, Wishard Memorial Hospital, 1001 West 10th Street, Indianapolis, Indiana 46202, USA*
- D. Blaschke, *Psychiatrische Klinik und Poliklinik, Nervenlinik der Universität München, Nussbaumstrasse 7, 8000 München 2, FRG*
- S. Brion, *Department of Psychiatry, CHU Timone, 13005 Marseille, France*
- G. L. Cooper, *Director of Clinical Research, Europe, Lilly Research Centre Ltd, Windlesham, Surrey, UK*
- J. M. Danion, *Department of Psychiatry, Hopital de la Grave, 31300 Toulouse, France*
- H. Dufour, *Department of Psychiatry, CHU, Timone, 13005 Marseille, France*
- N. A. Farid, *Department of Medicine, Indiana University School of Medicine, Indiana, USA*
- J. P. Feighner, *Feighner Research Institute, 1011 Devonshire Drive, Suite E, Encinitas, California 92024, USA*
- G. Ferrey, *Department of Psychiatry, CHS, 95600 Eubonne, France*
- R. W. Fuller, *Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA*
- J. Gailledreau, *Department of Psychiatry, Hopital Richaud, 7800 Versailles, France*
- J. R. Hall, *Associate Medical Director, Eli Lilly and Company Limited, City Wall House, Basing View, Basingstoke, Hampshire RG21 2LA, UK*
- J. Halper, *Department of Psychiatry, Payne Whitney Psychiatric Clinic, The New York Hospital, Cornell Medical Centre, 525 East 68th Street, New York, New York 10021, USA*
- I. Hindmarch, *Human Psychopharmacology Research Unit, University of Leeds, Leeds LS2 9JT, UK*
- G. Laakman, *Psychiatrische Klinik und Poliklinik, Nervenlinik der Universität München, Nussbaumstrasse 7, 8000 München, FRG*
- M. H. Lader, *Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK*
- X. Laqueille, *Department of Psychiatry, Hopital Richaud, 7800 Versailles, France*
- L. Lemberger, *Department of Pharmacology, Indiana University School of Medicine, Indiana, USA*
- J. J. López-Ibor, Jr, *Clinico López-Ibor, Av. Nueva Zelanda 44, E-28035 Madrid, Spain*
- J. J. Mann, *Department of Psychiatry, Payne Whitney Psychiatric Clinic, The New York Hospital, Cornell Medical Centre, 525 East 68th Street, New York, New York 10021, USA*
- J. Mendlewicz, *Cliniques Universitaires de Bruxelles, Hopital Erasme, Université Libre de Bruxelles, Route de Lennik 808, B-1070, Bruxelles, Belgium*
- S. A. Montgomery, *Academic Department of Psychiatry, St Mary's Hospital, Praed Street, London W2 1NY, UK*

- N. Parant-Lucena, *Department of Psychiatry, Hopital de la Grave, 31300 Toulouse, France*
- P. Pichot, *24 rue des Fossés Saint-Jacques, 75005 Paris, France*
- M. A. Pierredon, *Lilly France, 92213 Saint Cloud, France*
- M. J. Schmidt, *Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA*
- L. Singer, *Department of Psychiatry, Hospices Civils 67091, Strasbourg, France*
- J. F. Wernicke, *Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA*
- R. L. Wolen, *Department of Psychiatry, Indiana University Medical School, Indiana, USA*
- D. T. Wong, *Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA*